Onivyde (irinotecan liposome injection)

ONIVYDE is a prescription medicine used to treat pancreatic cancer which has spread to other parts of the body (become metastatic). Please call at M: +91 9891296838 to buy and know more details about the generic FDA approved Nivolumab medicine available in India and its cost price.

Onivyde is indicated, in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. ONIVYDE(irinotecan liposome injection) should be administered under the supervision of a qualified physician experienced in the uses of cancer chemotherapeutic agents.

Where can I buy Onivyde?

Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its presence PAN India with over 20 years of domain experience.

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Onivyde (irinotecan liposome injection) on prescription and Import License in Patient's Name only.

For Onivyde or (irinotecan liposome injection) price in India.
Please contact +91 9811747774 or neeraj@indianpharmanetwork.co.in

Get In Touch

Facilitator under Patient Assistance Programs In India

For Indian Patients, doctors and hospitals Onivyde (irinotecan liposome injection) can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Dosage Forms and Strengths

Injection: 43 mg/10 mL single dose vial .

FDA Approval Summary

ONIVYDE® (irinotecan liposome for injection) has Received Approval in Canada for the Treatment of Metastatic Adenocarcinoma of the Pancreas in the Post-Gemcitabine Setting(1)
August 11, 2017